These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 18075852)

  • 1. Cannabinoid CB(2)-selective inverse agonist protects against antigen-induced bone loss.
    Lunn CA; Fine J; Rojas-Triana A; Jackson JV; Lavey B; Kozlowski JA; Hipkin RW; Lundell DJ; Bober L
    Immunopharmacol Immunotoxicol; 2007; 29(3-4):387-401. PubMed ID: 18075852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo.
    Lunn CA; Fine JS; Rojas-Triana A; Jackson JV; Fan X; Kung TT; Gonsiorek W; Schwarz MA; Lavey B; Kozlowski JA; Narula SK; Lundell DJ; Hipkin RW; Bober LA
    J Pharmacol Exp Ther; 2006 Feb; 316(2):780-8. PubMed ID: 16258021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies.
    Lavey BJ; Kozlowski JA; Hipkin RW; Gonsiorek W; Lundell DJ; Piwinski JJ; Narula S; Lunn CA
    Bioorg Med Chem Lett; 2005 Feb; 15(3):783-6. PubMed ID: 15664857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
    Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
    Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists.
    Lunn CA; Reich EP; Fine JS; Lavey B; Kozlowski JA; Hipkin RW; Lundell DJ; Bober L
    Br J Pharmacol; 2008 Jan; 153(2):226-39. PubMed ID: 17906679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB2) in rodents and primates.
    Gonsiorek W; Lunn CA; Fan X; Deno G; Kozlowski J; Hipkin RW
    Br J Pharmacol; 2007 Aug; 151(8):1262-71. PubMed ID: 17603556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.
    Cascio MG; Bisogno T; Palazzo E; Thomas A; van der Stelt M; Brizzi A; de Novellis V; Marabese I; Ross R; van de Doelen T; Brizzi V; Pertwee R; Maione S; Di Marzo V
    Br J Pharmacol; 2006 Oct; 149(4):431-40. PubMed ID: 16953186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists.
    Huffman JW; Zengin G; Wu MJ; Lu J; Hynd G; Bushell K; Thompson AL; Bushell S; Tartal C; Hurst DP; Reggio PH; Selley DE; Cassidy MP; Wiley JL; Martin BR
    Bioorg Med Chem; 2005 Jan; 13(1):89-112. PubMed ID: 15582455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of selective cannabinoid CB(1) and CB(2) receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis.
    Tambaro S; Casu MA; Mastinu A; Lazzari P
    Eur J Pharmacol; 2014 Apr; 729():67-74. PubMed ID: 24561047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of (3',5'-dichloro-2,6-dihydroxy-biphenyl-4-yl)-aryl/alkyl-methanone selective CB2 inverse agonist.
    Presley CS; Mustafa SM; Abidi AH; Moore BM
    Bioorg Med Chem; 2015 Sep; 23(17):5390-401. PubMed ID: 26275680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
    De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
    J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expansion of SAR studies on triaryl bis sulfone cannabinoid CB2 receptor ligands.
    Tong L; Shankar BB; Chen L; Rizvi R; Kelly J; Gilbert E; Huang C; Yang DY; Kozlowski JA; Shih NY; Gonsiorek W; Hipkin RW; Malikzay A; Lunn CA; Lundell DJ
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6785-9. PubMed ID: 20850969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor.
    Cox ML; Haller VL; Welch SP
    Eur J Pharmacol; 2007 Sep; 570(1-3):50-6. PubMed ID: 17588560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.
    Yrjölä S; Sarparanta M; Airaksinen AJ; Hytti M; Kauppinen A; Pasonen-Seppänen S; Adinolfi B; Nieri P; Manera C; Keinänen O; Poso A; Nevalainen TJ; Parkkari T
    Eur J Pharm Sci; 2015 Jan; 67():85-96. PubMed ID: 25447744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanisms.
    Michler T; Storr M; Kramer J; Ochs S; Malo A; Reu S; Göke B; Schäfer C
    Am J Physiol Gastrointest Liver Physiol; 2013 Jan; 304(2):G181-92. PubMed ID: 23139224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis.
    Gutierrez T; Farthing JN; Zvonok AM; Makriyannis A; Hohmann AG
    Br J Pharmacol; 2007 Jan; 150(2):153-63. PubMed ID: 17160008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists.
    Rempel V; Volz N; Hinz S; Karcz T; Meliciani I; Nieger M; Wenzel W; Bräse S; Müller CE
    J Med Chem; 2012 Sep; 55(18):7967-77. PubMed ID: 22916707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetrahydroindazole derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.
    Matthews JM; McNally JJ; Connolly PJ; Xia M; Zhu B; Black S; Chen C; Hou C; Liang Y; Tang Y; Macielag MJ
    Bioorg Med Chem Lett; 2016 Nov; 26(21):5346-5349. PubMed ID: 27671496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice.
    Cluny NL; Keenan CM; Duncan M; Fox A; Lutz B; Sharkey KA
    J Pharmacol Exp Ther; 2010 Sep; 334(3):973-80. PubMed ID: 20571060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice.
    Ueda Y; Miyagawa N; Matsui T; Kaya T; Iwamura H
    Eur J Pharmacol; 2005 Sep; 520(1-3):164-71. PubMed ID: 16153638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.